The thesis
PanicFade v4 bets that negative headline shocks are overreacted to and tend to revert toward fundamentals. Concretely, it buys large caps hit by sentiment below -0.4 while they are already oversold — RSI14 under 35 and trading below their 20-day SMA — and sizes into the panic. It exits on reversion (RSI14 back above 50 or price reclaiming the SMA20) and hard-stops on fresh lows accompanied by continued negativity, treating that as a genuine fundamental break rather than noise.
The design leans on recent sentiment-feedback literature (arXiv:2509.11970, 2025, plus corroborating work in JRFM). The universe is deliberately conservative: 24 mega-cap names across tech, financials, healthcare, staples, and energy — AAPL, MSFT, JPM, JNJ, XOM and peers — where reversion is more plausible than in speculative small caps.
Validation
This is where PanicFade v4 looks strongest. Walk-forward validation ran four folds spanning September 2021 through August 2026, and all four were positive. Returns climbed across the folds (1.6%, 3.88%, 10.14%, 21.7%), with the most recent out-of-sample window posting a 21.7% return at a 2.44 Sharpe and just a 2.6% max drawdown. The probabilistic Sharpe ratio (PSR) sits at a very high 0.985, and the deflated Sharpe ratio (DSR) of 0.56 — computed across 27 trials — suggests the edge survives a reasonable correction for selection bias, if not overwhelmingly.
The full-sample backtest returned 37.93% over 1,233 days (a 6.79% CAGR) with a 0.96 Sharpe, 9.3% max drawdown, and a 62.88% win rate over 530 trades. That is a respectable, controlled-risk profile rather than a spectacular one.
Recent activity
Here the picture is quieter. The last six scheduled runs — August 12 through August 19 — each executed zero trades and rejected zero candidates, leaving the book flat at $10,000 in cash. That is not a malfunction so much as a feature of the strategy: it only acts when its narrow entry conditions (deep negative sentiment and oversold technicals) line up simultaneously. In a calm, grinding-higher tape, PanicFade v4 simply waits. There have been no live trades to evaluate.
Strengths and risks
Strengths: genuinely robust validation — four-for-four positive folds, an improving OOS trend, and a high PSR. The conservative universe and multi-condition entry reduce the odds of catching a falling knife.
Risks worth flagging: the headline Sharpe of 0.96 is modest, and the DSR of 0.56 across 27 trials means the edge is real but not bulletproof against overfitting. Turnover is extremely high at roughly 5,800%, implying heavy trading whose fees and slippage could erode the edge in live conditions. And the current dormancy cuts both ways — disciplined patience, yes, but also a strategy that contributes nothing until volatility returns. The real test comes with the next genuine panic, not this quiet stretch of cash.